Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response
Open accessThe DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
Abstract
Cdc25C and p53 have been reported to be physiological targets of checkpoint kinase 2 (Chk2). Surprisingly, although Chk2 purified from DNA damage sustaining cells has dramatically increased ability to phosphorylate Cdc25C when compared with untreated cells, its ability to phosphorylate p53 is weak before treatment, and there is no increase in its activity toward p53 after DNA damage by gamma irradiation or the radiomimetic agent neocarzinostatin. Furthermore, introduction of Chk2 short interfering RNA into three different human tumor cell lines leads to marked reduction of Chk2 protein, but p53 is still stabilized and active after DNA damage. The results with Chk1 short interfering RNA indicate as well that Chk1 does not play a role in human p53 stabilization after DNA damage. Thus, Chk1 and Chk2 are unlikely to be regulators of p53 in at least some human tumor cells. We discuss our results in the context of previous findings demonstrating a requirement for Chk2 in p53 stabilization and activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mutations of phosphorylation sites for these kinases on p53 and MDM2 or siRNA knockdown of Chk1 and Chk2 kinases lead to partial or no phenotypes (Wu et al, 2002;Ahn et al, 2003;Chao et al, 2003;Sluss et al, 2004), suggesting that additional targets and mechanisms may also contribute to activation of p53 after DNA damage.”
From ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage (2005) · cites this paper as Ahn et al, 2003
Experimental — accuracy not yet measuredIn the citing paper
“A major caveat of this interpretation is that Chk2 does not seem to play an essential role in G2 arrest 84,85,72 and it is more likely that damaged cells progress into mitosis due to inefficient Chk1 activation 86 and/or lack of robust p21 induction.”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Self-citationActivation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Self-citationLiu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625
Research works printed but not linked: 5
- Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H., and Canman, C. E. (2000) Cancer Res. 60, 5934 -5936
- Dumaz, N., Milne, D. M., Jardine, L. J., and Meek, D. W. (2001) Biochem. J. 359, 459 -464 · doi:10.1042/bj3590459 · Paper page
- Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., Blomqvist, C., Aittomaki, K., and Nevanlinna, H. (2001) Cancer Res. 61, 5718 -5722
- Matsuoka, S., Nakagawa, T., Masuda, A., Haruki, N., Elledge, S. J., and Takahashi, T. (2001) Cancer Res. 61, 5362-5365
- Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995) Cancer Res. 55, 5187-5190
Cited by
p53: traffic cop at the crossroads of DNA repair and recombination
Sengupta, S., & Harris, C. C. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1546 · Cited by 544
DNA damage-induced activation of ATM and ATM-dependent signaling pathways
Kurz, E. U., & Lees-Miller, S. P. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.029 · Cited by 478
CHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455
“Subsequent studies disputed this finding (Ahn et al., 2003; Jallepalli et al., 2003).”
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Kajita, M., McClinic, K. N., & Wade, P. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7559-7566.2004 · Cited by 333
A Role for the Deubiquitinating Enzyme USP28 in Control of the DNA-Damage Response
Zhang, D., Zaugg, K., Mak, T. W., & Elledge, S. J. (2006) · Cell · doi:10.1016/j.cell.2006.06.039 · Cited by 326
Senescence from G2 arrest, revisited
Gire, V., & Dulić, V. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000134 · Cited by 300
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2251 · Cited by 288
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy
Castedo, M., Perfettini, J.-L., Roumier, T., Valent, A., Raslova, H., Yakushijin, K., Horne, D., Feunteun, J., Lenoir, G., Medema, R., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207572 · Cited by 291
Control of the G2/M Transition
Stark, G. R., & Taylor, W. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:3:227 · Cited by 279
Ataxia-telangiectasia-like disorder (ATLD)—its clinical presentation and molecular basis
Taylor, A. M. R., Groom, A., & Byrd, P. J. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.04.009 · Cited by 269
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage
Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600812 · Cited by 260
“The samples were boiled and fractionated on SDS–PAGE and subjected to Western blot analysis using phosphorylation-specific antibodies.”
BackgroundMethodInfluentialAhn, J., Urist, M., & Prives, C. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.033 · Cited by 240
Self-citationp73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2
Urist, M., Tanaka, T., Poyurovsky, M. V., & Prives, C. (2004) · Genes & Development · doi:10.1101/gad.1221004 · Cited by 234
Self-citationOu, Y.-H., Chung, P.-H., Sun, T.-P., & Shieh, S.-Y. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0689 · Cited by 198
Chk1 in the DNA damage response: conserved roles from yeasts to mammals
Chen, Y., & Sanchez, Y. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.003 · Cited by 196
The Role of Nitric Oxide in Cancer: Master Regulator or NOt?
Khan, F. H., Dervan, E., Bhattacharyya, D. D., McAuliffe, J. D., Miranda, K. M., & Glynn, S. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249393 · Cited by 180
Structure and Activation Mechanism of the CHK2 DNA Damage Checkpoint Kinase
Cai, Z., Chehab, N. H., & Pavletich, N. P. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.007 · Cited by 180
Medema, R. H., & Macůrek, L. (2012) · Oncogene · doi:10.1038/onc.2011.451 · Cited by 177
p53 Stabilization and Accumulation Induced by Human Vaccinia-Related Kinase 1
Vega, F. M., Sevilla, A., & Lazo, P. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10366-10380.2004 · Cited by 156
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Zinc-finger protein-targeted gene regulation: Genomewide single-gene specificity
Tan, S., Guschin, D., Davalos, A., Lee, Y.-L., Snowden, A. W., Jouvenot, Y., Zhang, H. S., Howes, K., McNamara, A. R., Lai, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2035056100 · Cited by 153
E2F1 Uses the ATM Signaling Pathway to Induce p53 and Chk2 Phosphorylation and Apoptosis
Powers, J. T., Hong, S., Mayhew, C. N., Rogers, P. M., Knudsen, E. S., & Johnson, D. G. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.203.2.4 · Cited by 152
The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 153
Maclaine, N. J., & Hupp, T. R. (2009) · Aging · doi:10.18632/aging.100047 · Cited by 130
Phosphorylation of pRB at Ser612 by Chk1/2 leads to a complex between pRB and E2F‐1 after DNA damage
Inoue, Y., Kitagawa, M., & Taya, Y. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601652 · Cited by 141
Tumor Suppressor CHK2: Regulator of DNA Damage Response and Mediator of Chromosomal Stability
Stolz, A., Ertych, N., & Bastians, H. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1215 · Cited by 136
Li, L., & Zou, L. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20355 · Cited by 115
Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks
Buscemi, G., Perego, P., Carenini, N., Nakanishi, M., Chessa, L., Chen, J., Khanna, K. K., & Delia, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207986 · Cited by 146
Tools for target identification and validation
Wang, S., Sim, T. B., Kim, Y.-S., & Chang, Y. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.001 · Cited by 110
CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage
Schmitt, E., Boutros, R., Froment, C., Monsarrat, B., Ducommun, B., & Dozier, C. (2006) · Journal of Cell Science · doi:10.1242/jcs.03200 · Cited by 121
Haoudi, A., Daniels, R. C., Wong, E., Kupfer, G., & Semmes, O. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301649200 · Cited by 96
Tse, A. N., & Schwartz, G. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0841 · Cited by 92
Genetic instability in cancer cells by impaired cell cycle checkpoints
Nakanishi, M., Shimada, M., & Niida, H. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00289.x · Cited by 105
Lossaint, G., Besnard, E., Fisher, D., Piette, J., & Dulić, V (2011) · Oncogene · doi:10.1038/onc.2011.135 · Cited by 83
“Chk1 might be the major G2/M checkpoint regulator (Ahn et al., 2003; Jallepalli et al., 2003; Syljuasen et al., 2006; Jin et al., 2008; Zhang et al., 2008).”
InfluentialUncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case–control study
Brennan, P., McKay, J., Moore, L. E., Zaridze, D. G., Mukeria, A., Szeszenia‐Dabrowska, N., Lissowska, J., Rudnai, P., Fabiánová, E., Mateș, D., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm127 · Cited by 80
A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint
Beckerman, R., Donner, A. J., Mattia, M., Peart, M. J., Manley, J. L., Espinosa, J. M., & Prives, C. (2009) · Genes & Development · doi:10.1101/gad.1795709 · Cited by 69
Self-citationThe S phase checkpoint: When the crowd meets at the fork
GOTTIFREDI, V, & PRIVES, C. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.02.011 · Cited by 68
Self-citationKilkenny, M. L., Doré, A. S., Roe, S. M., Nestoras, K., Ho, J. C. Y., Watts, F. Z., & Pearl, L. H. (2008) · Genes & Development · doi:10.1101/gad.472808 · Cited by 62
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo
Niida, H., Murata, K., Shimada, M., Ogawa, K., Ohta, K., Suzuki, K., Fujigaki, H., Khaw, A. K., Banerjee, B., Hande, M. P., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.218 · Cited by 60
Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth
Han, L., Rajasekaran, B., Krisky, D. M., Bein, K., Grandi, P., Cohen, J. B., & Glorioso, J. C. (2008) · Virology · doi:10.1016/j.virol.2008.01.038 · Cited by 63
Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins
Tachikawa, K., Schröder, O., Frey, G., Briggs, S. P., & Sera, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406473101 · Cited by 59
Craig, A. L., Chrystal, J. A., Fraser, J. A., Sphyris, N., Lin, Y., Harrison, B. J., Scott, M. T., Dornreiter, I., & Hupp, T. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01595-06 · Cited by 54
Maas, K., Westfall, M., Pietenpol, J., Olsen, N. J., & Aune, T. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20931 · Cited by 51
Early Events in the DNA Damage Response
Ward, I. M., & Chen, J. (2004) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(04)63001-8 · Cited by 59
Burch, L. R., Scott, M. T., Pöhler, E., Meek, D. W., & Hupp, T. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.10.081 · Cited by 60
Identification of novel,in vivoactive Chk1 inhibitors utilizing structure guided drug design
Massey, A. J., Stokes, S. P., Browne, H. L., Foloppe, N., Fiumana, A., Scrace, S., Fallowfield, M., Bedford, S. T., Webb, P., Baker, L. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5929 · Cited by 46
DNA Damage Checkpoints and Cancer
Shimada, M., & Nakanishi, M. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9039-4 · Cited by 57
MacLaine, N. J., Øster, B., Bundgaard, B. B., Fraser, J. A., Buckner, C., Lazo, P. A., Meek, D. W., Höllsberg, P., & Hupp, T. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804433200 · Cited by 44
ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven
Wang, J., Wiltshire, T. D., Wang, Y., Mikell, C., Burks, J., Cunningham, C., Laar, E. S. V., Waters, S. J., Reed, E., & Wang, W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400015200 · Cited by 48
ATM and Genome Maintenance: Defining Its Role in Breast Cancer Susceptibility
Khanna, K. K., & Chenevix‐Trench, G. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048772.92326.a1 · Cited by 49
Tse, A. N., Sheikh, T. N., Ho, A. L., Chou, T., & Schwartz, G. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050807 · Cited by 50
Ganzinelli, M., Carrassa, L., Crippa, F., Tavecchio, M., Broggini, M., & Damia, G. L. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0304 · Cited by 48
Wu, J., Lai, G., Wan, F., Xiao, Z., Zeng, L., Wang, X., Ye, F., & Lei, T. (2012) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.226.267 · Cited by 42
Radioprotection by Hymenialdisine-Derived Checkpoint Kinase 2 Inhibitors
Nguyen, T. N., Saleem, R. S. Z., Luderer, M. J., Hovde, S., Henry, R. W., & Tepe, J. J. (2011) · ACS Chemical Biology · doi:10.1021/cb200320c · Cited by 43
DNA damage-induced signalling in ataxia-telangiectasia and related syndromes
Lavin, M. F., & Kozlov, S. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.04.032 · Cited by 42
Jack, M. T., Woo, R. A., Motoyama, N., Takai, H., & Lee, P. W. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309917200 · Cited by 39
Soubeyrand, S., Schild‐Poulter, C., & Haché, R. J. G. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04319.x · Cited by 35
Intrasteric regulation of MDM2
Shimizu, H., & Hupp, T. R. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00140-3 · Cited by 39
Loss of the tumour-suppressor genes CHK2 and BRCA1 results in chromosomal instability
Stolz, A., Ertych, N., & Bastians, H. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381704 · Cited by 31
RETRACTED: Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors
Pires, I. M., Ward, T. H., & Dive, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00607.x · Cited by 30
RetractedBRCA1 is regulated by Chk2 in response to spindle damage
Chabalier-Taste, C., Racca, C., Dozier, C., & Larminat, F. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.08.006 · Cited by 32
Improving the selectivity of cancer treatments by interfering with cell response pathways
Damia, G. L. M., & Broggini, M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.07.020 · Cited by 29
Kim, W.-J., Beardsley, D. I., Adamson, A. W., & Brown, K. D. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.009 · Cited by 31
Bhonde, M., Hanski, M., Magrini, R., Moorthy, N. D., Müller, A., Sausville, E. A., Kohno, K., Wiegand, P., Daniel, P. T., Zeitz, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207842 · Cited by 28
Déry, U., & Masson, J. (2007) · DNA repair · doi:10.1016/j.dnarep.2006.12.009 · Cited by 30
Chen, Y., Miao, Z., Zhao, W., & Ding, J. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.05.053 · Cited by 25
Role of Chk1 and Chk2 in Ara‐C‐induced differentiation of human leukemia K562 cells
Takagaki, K., Katsuma, S., Kaminishi, Y., Horio, T., Tanaka, T., Ohgi, T., & Yano, J. (2005) · Genes to Cells · doi:10.1111/j.1365-2443.2005.00821.x · Cited by 24
Liang, X., Guo, Y., Figg, W. D., Fojo, A. T., Mueller, M. D., & Yu, J. (2010) · Chemotherapy Research and Practice · doi:10.1155/2011/715469 · Cited by 23
The p53 Tumor Suppressor Pathway and Cancer
Zambetti, G. P. (2005) · Springer eBooks · doi:10.1007/0-387-30127-5 · Cited by 24
Regulation of p53-dependent transcription
Jõers, A. (2004) · DSpace repository (University of Tartu) · Cited by 248
Mammalian DNA Damage Response Pathway
Lou, Z., & Chen, J. (2006) · Springer eBooks · doi:10.1007/1-4020-3764-3_15 · Cited by 22
A Three-Phase Algorithm for Computer Aided siRNA Design
Zhou, H., Zeng, X., Wang, Y., & Seyfarth, B. R. (2006) · Informatica · doi:10.31449/inf.v30i3.103 · Cited by 16
Furusawa, Y., Yamanouchi, Y., Iizumi, T., Zhao, Q., Mitsuhashi, Y., Morita, A., Enomoto, A., Tabuchi, Y., & Kondo, T. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1402-2 · Cited by 16
KIM, J.-Y., Choi, H., Lee, H., Shin, J., SHIN, D.-H., Choi, J., Lee, Y. S., & Lee, K. (2015) · Oncology Reports · doi:10.3892/or.2015.3871 · Cited by 14
Analysis of p53 Gene Alterations in Cancer: A Critical View
Soussi, T. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_12 · Cited by 18
Distinct DNA damage determines differential phosphorylation of Chk2
Ouchi, M., & Ouchi, T. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.972823 · Cited by 11
14-3-3σ and p21 synergize to determine DNA damage response following Chk2 inhibition
Meng, S., Arbit, T., Veeriah, S., Mellinghoff, I. K., Fang, F., Vivanco, I., Rohle, D., & Chan, T. A.-T. (2009) · Cell Cycle · doi:10.4161/cc.8.14.8998 · Cited by 11
Tissue-specific regulation of checkpoint kinase 2 expression by p53
Chin, M. Y., & Li, G. (2003) · Experimental and Molecular Pathology · doi:10.1016/s0014-4800(03)00088-1 · Cited by 7
Peralta-Sastre, A., Manguán-García, C., de Luis, A., Belda-Iniesta, C., Moreno, S., Perona, R., & Sánchez‐Pérez, I. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.011 · Cited by 6
Chk2 Protects against Radiation-Induced Genomic Instability
MacLaren, A., Slavin, D. A., & McGowan, C. H. (2009) · Radiation Research · doi:10.1667/rr1603.1 · Cited by 6
Mutation analysis of the checkpoint kinase 2 gene in colorectal cancer cell lines
Liu, W., Zhong, B., Yang-de, Z., & Choi, G. (2007) · Chinese Medical Journal · doi:10.1097/00029330-200712010-00010 · Cited by 5
An inducible T7 RNA polymerase-dependent plasmid system for the expression of short hairpin RNAs
Hamdorf, M., Muckenfuß, H., Tschulena, U., Pleschka, S., Sanzenbacher, R., Cichutek, K., & Flory, E. (2006) · Molecular Biotechnology · doi:10.1385/mb:33:1:13 · Cited by 4
Using Transcriptomics to Evaluate Thresholds in Genotoxicity Dose–Response
McMullen, P. D., Pendse, S. N., Adeleye, Y. A., Carmichael, P. L., Andersen, M. E., & Clewell, R. A. (2016) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624059-00185 · Cited by 4
PARP Activity Fine-tunes the DNA Replication Choreography of Chk1-depleted Cells
Calzetta, N. L., Besteiro, M. A. G., & Gottifredi, V. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166949 · Cited by 6
P53 Links Tumor Development to Cancer Therapy
Hemann, M. T., & Lowe, S. W. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_15 · Cited by 2
CHK2 is Negatively Regulated by Protein Phosphatase 2A
Freeman, A. K. (2010) · Digital Commons - University of South Florida (University of South Florida)
CHEK2 in Breast and Colorectal Cancer
Kilpivaara, O. (2007) · Työväentutkimus Vuosikirja
Novel Role of CHK2 in the Intrinsic and Extrinsic Apoptosis Pathway
Agarwal, A. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7ng4nnv
Importance de la voie Cdk4-EZH2 dans l'échappement à la sénescence induite par la chimiothérapie
Gouju, J. (2016) · theses.fr (ABES) · doi:10.70675/be4fffa5zf97az4809z86f7z687238fb7187
INTEGRACIÓN DE LA FUNCIÓN DE VRK2 EN LAS RUTAS DE SEÑALIZACIÓN DE JNK Y P53.
Blanco, S. (2006) · DIGITAL.CSIC (Spanish National Research Council (CSIC))
Characterization of an autoimmune gene expression signature.
Maas, K. H. (2006)
Susceptibility genes in hereditary breast cancer
Vahteristo, P. (2003) · Helda - University of Helsinki Institutional Repository
POSTRANSLATIONAL MODIFICATIONS OF P53: UPSTREAM SIGNALING PATHWAYS.
ANDERSON, C. W. A., & (US), D. (2003) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.2172/15006423
Pereira, E., Solis, W. A., & Sánchez, Y. (2009) · AfCS-Nature Molecule Pages · doi:10.1038/mp.a000643.01
Posttranslational Modifications of p53: Upstream Signaling Pathways
Anderson, C. W., & Appella, E. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_5
Localisation et fonction de CHK2 en mitose
Chouinard, G. (2012) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/31174
Zhang, H., Tian, D., Zhang, W., Zhang, Y., Feng, J., Sheng, J., & Shang, X. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70678
Mécanismes orchestrant la sortie du cycle cellulaire opérant en G2
Lossaint, G. (2010) · theses.fr (ABES) · doi:10.70675/73a8a635z0ba0z466bza623zfba090ad12ce
Metadata
- Authors
- Ahn, J., Urist, M., & Prives, C.
- Affiliations
- Columbia University (US)
- Corresponding author
- Prives, Carol
- ORCID
- Prives, Carol
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-06
- Volume
- 278
- Issue
- 23
- Pages
- 20480-20489
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2114647652
- Cited by
- 99
- References
- 63
- Citations by year
- 2026: 1 · 2021: 1 · 2020: 1 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 4 · 2012: 2
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6342 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA87497)
- National Cancer Institute (CA-87497, P01CA087497)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- checkpoint kinase 2, Chk2, p53, Cdc25C, DNA damage response, p53 stabilization, Chk1, protein phosphorylation, gamma irradiation, neocarzinostatin, cancer cell lines, siRNA
- MeSH terms
- Checkpoint Kinase 1, Colonic Neoplasms, DNA Damage, Gamma Rays, Humans, Zinostatin, Phosphorylation, Protein Kinases, Substrate Specificity, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Nucleic Acid Synthesis Inhibitors, cdc25 Phosphatases, Checkpoint Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.